News and Articles
Follow A Race Against Blindness research funding, inherited retinal disease developments, community stories, grant announcements, and updates from families racing toward sight-saving treatments.
Featured article
A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)
Newly added funding closes critical gap and enables planned trial initiation in early 2026
Latest Posts
Is A Race Against Blindness Legit? Because Independent Platforms Verify Us
Is a race against blindness legit? Learn how independent platforms like the IRS, Candid, and Charity Navigator verify our nonprofit status and transparency.
A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)
Newly added funding closes critical gap and enables planned trial initiation in early 2026
Why Patient Advocacy Matters More Than Ever in Rare Disease Gene Therapy
Patient advocacy is now one of the most powerful drivers of progress in retinal gene therapy. Learn how nonprofit involvement, family voices, awareness, and fundraising are accelerating research for Bardet-Biedl Syndrome and inherited retinal diseases — and why this work matters now more than ever.
Inside the Gene Therapy for Ophthalmic Disorders Summit: What We Learned and Why It Matters for Families Facing Vision Loss
We recently attended the Gene Therapy for Ophthalmic Disorders Summit, where leading researchers and clinicians shared promising advances in retinal gene therapy. From new vision endpoints to breakthroughs in delivery methods and patient advocacy, the conference highlighted real progress toward treatments for BBS, RP, and other inherited retinal diseases. Here’s what we learned — and why it matters for families urgently waiting for hope.
How New Gene Therapy Innovations Could Accelerate Treatment for Bardet-Biedl Syndrome and Inherited Retinal Diseases
The latest innovations in gene therapy — from optogenetics to engineered AAV capsids to AI-driven breakthroughs — are rapidly accelerating progress toward treatments for Bardet-Biedl Syndrome and other inherited retinal diseases. Here’s what these advances mean for families urgently awaiting hope.